Mostrar el registro sencillo del ítem
dc.contributor.author | García Lescano, Héctor Hugo | |
dc.contributor.author | Castillo Berrios, Yesenia | |
dc.contributor.author | Gonzales, Isidro | |
dc.contributor.author | Bustos Palomino, Javier Arturo | |
dc.contributor.author | Saavedra Pastor, Herbert | |
dc.contributor.author | Jacob, Louis | |
dc.contributor.author | Del Brutto, Oscar H. | |
dc.contributor.author | Wilkins, Patricia P. | |
dc.contributor.author | Gonzalez Zariquiey, Armando Emiliano | |
dc.contributor.author | Gilman, Robert Hugh | |
dc.contributor.author | Cysticercosis Working Group in Peru | |
dc.date.accessioned | 2018-11-30T17:17:15Z | |
dc.date.available | 2018-11-30T17:17:15Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/4113 | |
dc.description.abstract | OBJECTIVE: To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa® and Ridascreen® , for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentil-lectin purified glycoprotein antigens). METHODS: Archive serum samples from patients with viable NCC (n = 45) or resolved, calcified NCC (n = 45), as well as sera from patients with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45), were evaluated for cysticercosis antibody detection using two ELISA kits, Novalisa® and Ridascreen® . All NCC samples had previously tested positive, and all samples from heterologous infections were negative on LLGP-EITB for cysticercosis. Positive rates were calculated by kit and sample group and compared between the two kits. RESULTS: Compared to LLGP-EITB, the sensitivity of both ELISA assays to detect specific antibodies in patients with viable NCC was low (44.4% and 22.2%), and for calcified NCC, it was only 6.7% and 4.5%. Sera from patients with cystic hydatid disease were highly cross-reactive in both ELISA assays (38/45, 84.4%; and 25/45, 55.6%). Sera from patients with hymenolepiasis cross-reacted in five cases in one of the assays (11.1%) and in only one sample with the second assay (2.2%). CONCLUSIONS: The performance of Novalisa® and Ridascreen® was poor. Antibody ELISA detection cannot be recommended for the diagnosis of neurocysticercosis. | en_US |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.relation.ispartofseries | Tropical Medicine and International Health | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Peru | en_US |
dc.subject | Neurocysticercosis | en_US |
dc.subject | Taenia solium | en_US |
dc.subject | neurocysticercosis | en_US |
dc.subject | Animals | en_US |
dc.subject | Antigens, Helminth | en_US |
dc.subject | Enzyme-Linked Immunosorbent Assay | en_US |
dc.subject | Sensitivity and Specificity | en_US |
dc.subject | antibody | en_US |
dc.subject | cysticercosis | en_US |
dc.subject | ELISA | en_US |
dc.subject | anticorps | en_US |
dc.subject | cysticercose | en_US |
dc.subject | Immunologic Tests | en_US |
dc.subject | Immunomagnetic Separation | en_US |
dc.subject | neurocysticercose | en_US |
dc.subject | Pérou | en_US |
dc.title | Low sensitivity and frequent cross-reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1111/tmi.13010 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.06 | |
dc.relation.issn | 1365-3156 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |